Objective To evaluate the clinical efficacy of Chu-Needle Therapy combined with Kang'ai Injection in treating cancer-related fatigue(CRF)in colorectal cancer patients with qi-blood deficiency syndrome.Methods Eighty patients diagnosed with colorectal cancer accompanied by CRF and qi-blood deficiency syndrome were enrolled from the inpatient and outpatient departments of Guangdong Second Traditional Chinese Medicine Hospital between January 2023 and March 2024.Participants were randomly divided into an observation group(n=40)and a control group(n=40)using a random number table.The control group received Kang'ai Injection alone,while the observation group received additional Chu-Needle Therapy.Treatment courses lasted 7 days each,with two consecutive courses administered.After two weeks,clinical efficacy was evaluated by comparing Revised Piper Fatigue Scale scores,traditional Chinese medicine(TCM)syndrome scores,as well as red blood cell count(RBC),hemoglobin(HGB),and albumin(ALB)levels,and immune markers(CD3+,CD4+,CD8+,NK cells)before and after treatment.Safety and adverse reactions were also assessed.Results(1)After treatment,both groups showed significant improvements in all Piper Fatigue Scale(PFS)scores,including behavioral,sensory,affective,and cognitive dimensions,as well as total scores(P＜0.05).The observation group demonstrated significantly greater improvements in all PFS subscales and total scores compared to the control group,with statistically significant differences(P＜0.05).(2)After treatment,both groups exhibited marked reductions in TCM syndrome scores,including fatigue,palpitations,shortness of breath,pale complexion,dizziness,spontaneous or night sweating,limb numbness,poor appetite,pale nails,and total scores(P＜0.05).The observation group showed significantly better improvement in all TCM syndrome scores than the control group,with statistically significant differences(P＜0.05).(3)The total effective rate was 82.5％(33/40)in the observation group versus 40.00％(16/40)in the control group,indicating significantly superior therapeutic efficacy in the observation group,with statistically significant differences(P＜0.05).(4)After treatment,both groups demonstrated significant improvements in RBC,HGB,ALB levels(P＜0.05),with the observation group showing significantly greater improvements in these hematological parameters compared to the control group,with statistically significant differences(P＜0.05).(5)After-treatment,both groups showed significant changes in immune markers CD3+,CD4+,CD8+,or NK cells compared to baseline(P＜0.05).The observation group exhibited significantly better modulation of CD3+,CD4+,CD8+,and NK cell levels than the control group,with statistically significant differences(P＜0.05).(6)The incidence of adverse reactions was 5.00％(2/40)in the observation group versus 22.50％(9/40)in the control group,indicating significantly better safety profile in the observation group,with statistically significant differences(P＜0.05).Conclusion Chu-Needle Therapy combined with Kang'ai Injection significantly alleviates fatigue,improves clinical symptoms,enhances nutritional status and immune function,and elevates quality of life in colorectal cancer patients with CRF and qi-blood deficiency syndrome,demonstrating notable clinical efficacy.

Objective To investigate the ischemic injury of hepatic cell caused by hepatic artery occlusion.Methods The hepatic artery was occluded in 20 dogs via operation,while the portal vein remained patent.Specimens were gained from the right liver at four time points:before occlusion of the hepatic artery,20(minutes),40 minutes and 60 minutes after artery occlusion.Each specimen was examined by HE and BCL-2 by immunohistochemistry.The gray scale of BCL-2 in HE sections was detected.Results Hepatic cellular injury was obvious 20 minutes after occlusion of the hepatic artery.Irreversible hepatic cellular injury was(observed) 60 minutes after hepatic artery occlusion.The results showed that the gray scale of BCL-2 at every time point after hepatic artery occlusion were significantly different from that before hepatic artery occlusion(P